

REMARKS

Applicants amend the Cross Reference to Related Applications to set forth the priority claim in the above-identified application.

Applicants cancel claims 2, 3, 10, 11, 26, and 27, directed to non-elected subject matter, without prejudice to applicants' ability to file and obtain patent protection for claims directed to this cancelled subject matter in applications claiming priority to the present application under 35 U.S.C. §120, and request examination of amended claims 1, 4-9, and 12-25.

Applicants amend claims 1 and 5 to replace the term "pharmaceutically acceptable derivative" with ---pharmaceutically acceptable salt---.

In light of the cancellation of claims 2 and 3, Applicants amend claims 4, 5, 13, and 16 to depend upon claim 1.

Claims 7 and 12 are amended to incorporate the specific compounds into the claim.


Claim 19 is amended to delete reference to "conditions associated with cell death" as suggested by the Examiner in the parent application.

Applicants amend claim 21 to delete reference to "(oral), lip, tongue, mouth, pharynx" as suggested by the Examiner in the parent application.

None of these amendments add any new matter.

Applicants respectfully request that the Examiner consider the foregoing remarks and enter the indicated amendments prior to substantive examination of this application.

Respectfully submitted,



Andrea L. C. Robidoux (Reg. No. 47,902)

Agent for Applicants

C/O Vertex Pharmaceuticals Inc.

130 Waverly St.

Cambridge, MA 02139-4242

Tel: (617)444-6731

Fax: (617)444-6483